Tovorilimab
Rectal Cancer Stage III
Beijing Friendship HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Rectal Cancer Stage III cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Fudan University | Phase 3 | BB |
Eloxatin Prof. Dr. med. Claus Rödel | Phase 3 | B |
Same molecule, other indications
Tovorilimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →